Profound Medical Corp (PROF)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $271.77M
Last updated: Nov 17, 2026 at 11:06 AM ET
Profound Medical Corp (PROF) Stock Forecast
Analysts expect Profound Medical (PROF) to earn -$0.93 per share in the fiscal year ending Dec 31, 2026, on revenue of $35.71M. Of 5 analysts, 5 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 2 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 5 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 5 | 100.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 5
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 71.0%.
- Fiscal year ending Dec 31, 2026
- -$0.93
- EPS consensus, revenue $35.71M
- Fiscal year ending Dec 31, 2027
- -$0.61
- EPS consensus, revenue $61.05M
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.93 | -$0.96 to -$0.90 | 4 | $35.71M | $35.12M to $36.22M | 4 |
| Dec 31, 2027 | -$0.61 | -$0.90 to -$0.07 | 5 | $61.05M | $54.56M to $65.38M | 5 |
Quarterly Estimates
The EPS consensus falls from -$0.19 for the quarter ending Dec 31, 2026 to -$0.22 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.19 | -$0.21 to -$0.19 | 5 | $8.85M | $7.64M to $11.03M | 5 |
| Mar 31, 2027 | -$0.22 | -$0.24 to -$0.18 | 3 | $11.88M | $11.61M to $12.27M | 3 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 2 upward and 1 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 2 | 0 |
| Quarter ending Mar 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$0.86.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.93 | -$0.84 | -$0.84 | -$0.86 | -$0.86 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.61 | -$0.59 | -$0.59 | -$0.59 | -$0.59 | N/A |
| Quarter ending Mar 31, 2027 | -$0.22 | -$0.21 | -$0.21 | -$0.21 | -$0.21 | N/A |
Frequently Asked Questions About PROF
What is the PROF stock forecast?
Consensus analyst estimates put Profound Medical's EPS at -$0.93 for the fiscal year ending Dec 31, 2026, on revenue of $35.71M. The consensus rating from 5 analysts is Buy.
How do analysts rate PROF stock?
Of 5 analysts covering Profound Medical, 0 rate it Strong Buy, 5 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from PROF next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.93, with estimates from -$0.96 to -$0.90 from 4 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.61, with estimates from -$0.90 to -$0.07 from 5 analysts.
What revenue do analysts expect from Profound Medical next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $35.71M, with estimates from $35.12M to $36.22M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $61.05M, with estimates from $54.56M to $65.38M.
How many analysts cover PROF?
5 analysts rate Profound Medical stock, and 4 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
PROF pages: Overview, Earnings, Forecast, Financials